source
- Astellas signs up to $1.34 billion option deal for Audax's DAX-044 immuno-oncology candidateAstellas Pharma announced it will pay up to $1.34 billion for an exclusive option to license Audax Biosciences' investigational antibody-cytokine fusion, DAX-044. The agreement includes an undiscl…
- FDA outlines pathway for approval of personalized gene-editing therapiesThe U.S. Food and Drug Administration released a set of recommendations describing how developers can pursue regulatory approval for gene-editing treatments that are customized to a single patient’…